• The therapies, it's just like finance and the markets went past the regulators, and drugs are biotech are going past the regulators.

    FORBES: Intelligent Investing Transcript

  • Some industry observers have said that Big Pharma firms should try to more actively license drugs from smaller companies and biotech outfits in order to fill out their pipelines of experimental drugs.

    FORBES

  • Amgen says it's impossible to make exact copies of biotech drugs and opposes automatic substitution.

    FORBES: OutFront

  • The acquisition will give Pfizer a much larger presence in areas where it has been viewed as weaker than the competition, namely biotech drugs and vaccines.

    FORBES: Magazine Article

  • Satellite communications, biotech drugs, and a few other industries have very high upfront costs.

    FORBES: Is Google Too Rushed to Pioneer?

  • Its homegrown pipeline of new drugs is rather thin, and competition to fill these gaps with drugs from biotech firms is fierce.

    ECONOMIST: Can Fred Hassan cure Schering-Plough?

  • In this case, the DNA was constructed for Microbia , another Cambridge biotech that is developing drugs and creating microbes that can be used in manufacturing chemicals.

    FORBES: Magazine Article

  • In June, the company announced that it was discontinuing work on two drugs, and, like most of the biotech sector, its stock has been battered: Shares are down more than 70% this year.

    FORBES: Magazine Article

  • Nonetheless, Berry says that most companies are "making solid progress" in development and clinical trials and that Big Pharma, with pipelines running dry and blockbuster drugs coming off-patent, needs biotech partners more than ever.

    FORBES: Will Biotech Boom Again?

  • It is working on better protein-based drugs, gene therapy, industrial enzymes, and ag-biotech.

    FORBES: The Next Big Move For The Smartest Biotech Investor

  • Taking aim at diabetes, arthritis, lupus, obesity and cancer, the biotech house now has 40 drugs in preclinical or patient trials, more than at any time in the company's history and up from only 22 during the entire 1990s.

    FORBES: Biotech Behemoth

  • In addition to Sugen and Genentech, research powerhouses Novartis and AstraZeneca and biotech boutique ImClone Systems are rushing to test new drugs as VEGF-blockers.

    FORBES: Targeting Tumors

  • For a variety of reasons, one could say that ZIOPHARM Oncology (ZIOP), a tiny little-known biopharmaceutical company developing several anti-cancer drugs, is now several notches above its peers in the highly volatile and competitive biotech industry.

    FORBES: ZIOPHARM Oncology: Why This Tiny Biotech Has Attracted Fidelity And Other Big Investors

  • Both biotech and pharmaceutical firms might argue that the next set of breakthrough drugs are just around the corner.

    FORBES: Magazine Article

  • Think of them as generic versions of biotech protein drugs, except, unlike traditional pills, these medicines are tough and complicated to make.

    FORBES: Amgen's Planned Assault On AbbVie, Roche, And Lilly

  • But drug and biotech companies have been slow to use genetic and biochemical information to create new drugs.

    FORBES: Magazine Article

  • The biotech company revolutionized antiviral treatments for HIV making the drugs bearable and has continued to transform medicine for the lethal disease.

    FORBES: Best Ideas 2013: Add Dose of Biotech, Avoid Plump Valuations In Dangerous Market

  • It's the key difference between his company and Bristol-Myers, which has licensed most of its cancer drugs from the government or biotech firms.

    FORBES: A Homegrown Pipeline

  • Because existing treatments have such a low cure rate and sometimes unbearable side effects, biotech and pharmaceutical companies have been racing to develop a new generation of better drugs.

    FORBES: Magazine Article

  • The goal is to move from having to merely tweak the proteins that are used as biotech drugs to being able to design them, even taking material from multiple organisms and using them to create new, functional genes.

    FORBES: Photoshop For DNA

  • Pfizer, Merck and Novartis have all said they intend to make a business of selling copycats of biotech drugs, protein medicines that have only been a force in medicine for a little over two decades.

    FORBES: Amgen And Watson Join Forces To Develop Generic Cancer Drugs

  • The tool is being used by 16 companies and research institutes, including Sequenom, a biotech firm in San Diego, California, and by the Indian government, to track drugs to treat a new strain of malaria.

    FORBES: Magazine Article

  • The biotech wants the agency to change the way it grants exclusivity to fixed-dose combination drugs and hopes to win its argument so that more revenue can be wrung out of its recently approved Stribild HIV treatment.

    FORBES: Gilead Challenges FDA Over Exclusivity For Its Latest AIDS Drug

  • The tool is being used by 16 companies and research institutes, including Sequenom, (nasdaq: SQNMD - news - people ) a biotech firm in San Diego, California, and by the Indian government, to track drugs to treat a new strain of malaria.

    FORBES: Consultants From Chennai

  • In its petition, the biotech notes that the FDA has denied exclusivity to 10 fixed-dose combination drugs containing both new and previously approved active moieties for nearly 20 years.

    FORBES: Gilead Challenges FDA Over Exclusivity For Its Latest AIDS Drug

  • One of biotech powerhouse Amgen's most profitable blockbuster drugs will come under the scrutiny of the House Ways and Means Committee in a hearing scheduled to begin at 10:30 Wednesday morning.

    FORBES: Magazine Article

  • The biotech firm has said that it is taking steps to refocus its business on developing drugs from proteins and that it is looking at spinning off units such as using animal organs in human transplants.

    BBC: Losses increase at biotech firm

  • Isis, which makes drugs that work by shutting down DNA, is seen by many in biotech as having a history of overpromising and underdelivering, although it is close to having one drug, for a rare form of high cholesterol, approved.

    FORBES: Biotech's Comeback Kid

  • Witty has abandoned me-too drugs--shutting down research into depression, anxiety, pain and other mature categories--and created 40 tiny biotech-style units that have autonomy.

    FORBES: On The Cover/Top Stories

  • It's the key difference between his company and Bristol-Myers, which has licensed most of its cancer drugs from the U.S. government or biotech companies.

    FORBES: Modesty ablaze

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定